vs
Aardvark Therapeutics, Inc.（AARD）与渤健（BIIB）财务数据对比。点击上方公司名可切换其他公司
Aardvark Therapeutics是一家处于临床阶段的生物制药企业，专注于研发针对炎症、代谢类疾病及罕见病的新型靶向疗法，核心管线聚焦G蛋白偶联受体相关药物，主要服务北美及全球患者群体，开展医药研发领域合作。
渤健是总部位于美国马萨诸塞州剑桥市的跨国生物技术企业，专注于神经系统疾病治疗领域。公司核心产品包括用于多发性硬化症的特菲达、万立能等多款药物，以及治疗脊髓性肌萎缩症的诺西那生钠、治疗弗里德赖希共济失调的Skyclarys，致力于为神经疾病和罕见病患者提供创新疗法。
AARD vs BIIB — 直观对比
营收规模更大
BIIB
是对方的Infinity倍
$0
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $0 | $2.3B |
| 净利润 | $-17.6M | $-48.9M |
| 毛利率 | — | 78.3% |
| 营业利润率 | — | -2.5% |
| 净利率 | — | -2.1% |
| 营收同比 | — | -7.1% |
| 净利润同比 | — | -118.3% |
| 每股收益（稀释后） | $-0.81 | $-0.35 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AARDBIIB
| Q4 25 | $0 | $2.3B | ||
| Q3 25 | $0 | $2.5B | ||
| Q2 25 | $0 | $2.6B | ||
| Q1 25 | $0 | $2.4B | ||
| Q4 24 | — | $2.5B | ||
| Q3 24 | — | $2.5B | ||
| Q2 24 | — | $2.5B | ||
| Q1 24 | — | $2.3B |
净利润AARDBIIB
| Q4 25 | $-17.6M | $-48.9M | ||
| Q3 25 | $-16.3M | $466.5M | ||
| Q2 25 | $-14.4M | $634.8M | ||
| Q1 25 | $-9.3M | $240.5M | ||
| Q4 24 | — | $266.7M | ||
| Q3 24 | — | $388.5M | ||
| Q2 24 | — | $583.6M | ||
| Q1 24 | — | $393.4M |
毛利率AARDBIIB
| Q4 25 | — | 78.3% | ||
| Q3 25 | — | 73.4% | ||
| Q2 25 | — | 77.1% | ||
| Q1 25 | — | 74.1% | ||
| Q4 24 | — | 76.2% | ||
| Q3 24 | — | 74.1% | ||
| Q2 24 | — | 77.8% | ||
| Q1 24 | — | 76.3% |
营业利润率AARDBIIB
| Q4 25 | — | -2.5% | ||
| Q3 25 | — | 22.0% | ||
| Q2 25 | — | 28.1% | ||
| Q1 25 | — | 12.8% | ||
| Q4 24 | — | 11.9% | ||
| Q3 24 | — | 18.3% | ||
| Q2 24 | — | 28.3% | ||
| Q1 24 | — | 20.3% |
净利率AARDBIIB
| Q4 25 | — | -2.1% | ||
| Q3 25 | — | 18.4% | ||
| Q2 25 | — | 24.0% | ||
| Q1 25 | — | 9.9% | ||
| Q4 24 | — | 10.9% | ||
| Q3 24 | — | 15.8% | ||
| Q2 24 | — | 23.7% | ||
| Q1 24 | — | 17.2% |
每股收益（稀释后）AARDBIIB
| Q4 25 | $-0.81 | $-0.35 | ||
| Q3 25 | $-0.75 | $3.17 | ||
| Q2 25 | $-0.66 | $4.33 | ||
| Q1 25 | $-0.71 | $1.64 | ||
| Q4 24 | — | $1.82 | ||
| Q3 24 | — | $2.66 | ||
| Q2 24 | — | $4.00 | ||
| Q1 24 | — | $2.70 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $110.0M | — |
| 总债务越低越好 | — | $6.3B |
| 股东权益账面价值 | $106.6M | $18.3B |
| 总资产 | $117.2M | $29.4B |
| 负债/权益比越低杠杆越低 | — | 0.34× |
8季度趋势，按日历期对齐
现金及短期投资AARDBIIB
| Q4 25 | $110.0M | — | ||
| Q3 25 | $126.3M | — | ||
| Q2 25 | $141.8M | — | ||
| Q1 25 | $151.3M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
总债务AARDBIIB
| Q4 25 | — | $6.3B | ||
| Q3 25 | — | $6.3B | ||
| Q2 25 | — | $6.3B | ||
| Q1 25 | — | $4.5B | ||
| Q4 24 | — | $6.3B | ||
| Q3 24 | — | $4.5B | ||
| Q2 24 | — | $6.3B | ||
| Q1 24 | — | $6.3B |
股东权益AARDBIIB
| Q4 25 | $106.6M | $18.3B | ||
| Q3 25 | $122.4M | $18.2B | ||
| Q2 25 | $136.9M | $17.6B | ||
| Q1 25 | $150.7M | $17.0B | ||
| Q4 24 | — | $16.7B | ||
| Q3 24 | — | $16.4B | ||
| Q2 24 | — | $15.9B | ||
| Q1 24 | — | $15.2B |
总资产AARDBIIB
| Q4 25 | $117.2M | $29.4B | ||
| Q3 25 | $133.2M | $29.2B | ||
| Q2 25 | $147.5M | $28.3B | ||
| Q1 25 | $157.0M | $28.0B | ||
| Q4 24 | — | $28.0B | ||
| Q3 24 | — | $28.3B | ||
| Q2 24 | — | $26.8B | ||
| Q1 24 | — | $26.6B |
负债/权益比AARDBIIB
| Q4 25 | — | 0.34× | ||
| Q3 25 | — | 0.35× | ||
| Q2 25 | — | 0.36× | ||
| Q1 25 | — | 0.27× | ||
| Q4 24 | — | 0.38× | ||
| Q3 24 | — | 0.28× | ||
| Q2 24 | — | 0.40× | ||
| Q1 24 | — | 0.41× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-16.8M | $511.9M |
| 自由现金流经营现金流 - 资本支出 | — | $468.0M |
| 自由现金流率自由现金流/营收 | — | 20.5% |
| 资本支出强度资本支出/营收 | — | 1.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $2.1B |
8季度趋势，按日历期对齐
经营现金流AARDBIIB
| Q4 25 | $-16.8M | $511.9M | ||
| Q3 25 | $-16.1M | $1.3B | ||
| Q2 25 | $-9.8M | $160.9M | ||
| Q1 25 | $-11.4M | $259.3M | ||
| Q4 24 | — | $760.9M | ||
| Q3 24 | — | $935.6M | ||
| Q2 24 | — | $625.8M | ||
| Q1 24 | — | $553.2M |
自由现金流AARDBIIB
| Q4 25 | — | $468.0M | ||
| Q3 25 | $-16.1M | $1.2B | ||
| Q2 25 | $-9.9M | $134.3M | ||
| Q1 25 | — | $222.2M | ||
| Q4 24 | — | $721.6M | ||
| Q3 24 | — | $900.6M | ||
| Q2 24 | — | $592.3M | ||
| Q1 24 | — | $507.3M |
自由现金流率AARDBIIB
| Q4 25 | — | 20.5% | ||
| Q3 25 | — | 48.4% | ||
| Q2 25 | — | 5.1% | ||
| Q1 25 | — | 9.1% | ||
| Q4 24 | — | 29.4% | ||
| Q3 24 | — | 36.5% | ||
| Q2 24 | — | 24.0% | ||
| Q1 24 | — | 22.1% |
资本支出强度AARDBIIB
| Q4 25 | — | 1.9% | ||
| Q3 25 | — | 1.8% | ||
| Q2 25 | — | 1.0% | ||
| Q1 25 | — | 1.5% | ||
| Q4 24 | — | 1.6% | ||
| Q3 24 | — | 1.4% | ||
| Q2 24 | — | 1.4% | ||
| Q1 24 | — | 2.0% |
现金转化率AARDBIIB
| Q4 25 | — | — | ||
| Q3 25 | — | 2.73× | ||
| Q2 25 | — | 0.25× | ||
| Q1 25 | — | 1.08× | ||
| Q4 24 | — | 2.85× | ||
| Q3 24 | — | 2.41× | ||
| Q2 24 | — | 1.07× | ||
| Q1 24 | — | 1.41× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AARD
暂无分部数据
BIIB
| Products | $1.7B | 73% |
| Tysabri Product | $244.5M | 11% |
| AVONEX | $119.2M | 5% |
| SKYCLARYS | $88.9M | 4% |
| Alzheimers Collaboration | $47.1M | 2% |
| IMRALDI | $43.5M | 2% |
| TECFIDERA | $36.9M | 2% |
| PLEGRIDY | $24.7M | 1% |
| QALSODY | $7.8M | 0% |
| BYOOVIZ | $4.3M | 0% |
